中文
Investors

Metabolic Diseases

Title Venue for presentation Type Time
GLP-1R/GIPR Peptide Agonist ASC31 + ASC47 Shows 119.6% More Weight Loss than Tirzepatide in DIO Mice ObesityWeek® 2025 Poster 11/2025
A full analysis of 28-Day MAD Study of Oral GLP-1R Biased Small Molecule Agonist ASC30 for obesity ObesityWeek® 2025 Poster 11/2025
ASC30, a Once-Monthly SQ Injected Small Molecule GLP-1RA in Participants with Obesity:A Ph Ib Study ObesityWeek® 2025 Poster 11/2025
ASC30, an Oral GLP-1R Biased Small Molecule Agonist Demonstrated Superior Weigh Loss in Participants with Obesity: A 28-Day Multiple Ascending Dose Study The 61st European Association for the Study of Diabetes
(EASD 2025) 		Short Oral Presentation 9/2025
ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model The American Diabetes Association's 85th Scientific Sessions
(ADA 2025)		 Poster 6/2025
ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study The American Diabetes Association's 85th Scientific Sessions
(ADA 2025)		 Poster 6/2025
ASC47, a Muscle-Preserving Weight Loss Drug Candidate in Healthy Participants: A First-in-human Single Ascending Dose Study The 32nd European Congress On Obesity (ECO 2025) Guided poster 5/2025
ASC47, An Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate For Obesity, Demonstrated Significant Weight Loss And Preserved Muscle In DIO Mice The 32nd European Congress On Obesity (ECO 2025) Oral 5/2025

Exploratory Indications

Title Venue for presentation Type Time
Denifanstat for moderate‐to‐severe acne: A Phase 2, randomized, double‐blind, placebo‐controlled trial Journal of the European Academy of Dermatology and Venereology Paper 11/2025
First-in-Class FASN Inhibitor Denifanstat Achieved All Endpoints in the Treatment of Acne Vulgaris: Results from a Phase Ⅲ Randomised Placebo Controlled Trial The European Academy of Dermatology and Venereology (EADV) Congress 2025 Oral Presentation 9/2025
First FASN inhibitor ASC40 to treat acne vulgaris patients: final results from a Phase 2 trial The 2024 American Academy of Dermatology (AAD) Annual Meeting e-Poster 3/2024
ASC40， an oral once-daily fatty acid synthase (FASN) inhibitor, in patients with acne vulgaris: topline results from a phase 2 randomized, double-blind, placebo-controlled, multicenter trial The European Academy of Dermatology and Venereology (EADV) Congress 2023 Poster 10/2023

  • © 2018 Ascletis Pharma Inc.

contact

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号 浙ICP备11050387号-1